NK cell depletion diminish tumour-specific B cell responses

Immunology Letters

Volumn 93, Issue 2-3, 2004, Pages 205-210

  Jensen, Markus ^a   Tawadros, Samir ^a   Sedlacek, Hans Harald ^b   Schultze, Joachim L ^a   Berthold, Frank ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Medinnova GmbH   (Germany)

Author keywords

Adaptive immunity; B cells; Cancer; Immunotherapy; Innate immunity; NK cells

Indexed keywords

GANGLIOSIDE GD2; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CANCER CELL; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY; DATA ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOCYTE DEPLETION; MOUSE; NATURAL KILLER CELL; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; TUMOR IMMUNITY; TUMOR IMMUNOLOGY;

ANIMALS; ANTIBODIES; ANTIBODY FORMATION; B-LYMPHOCYTES; CELL LINE, TUMOR; CELL TRANSPLANTATION; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; G(M1) GANGLIOSIDE; GANGLIOSIDES; HUMANS; IMMUNITY, NATURAL; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; MICE, SCID; NEOPLASMS, EXPERIMENTAL; VACCINATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 2442714817     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2004.03.015     Document Type: Article

References (23)

1. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3:2003;133-146
2. Barton G.M., Medzhitov R. Control of adaptive immune responses by Toll-like receptors. Curr. Opin. Immunol. 14:2002;380-383
3. Moretta A., Bottino C., Vitale M., Pende D., Cantoni C., Mingari M.C., et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19:2001;197-223
4. Janeway C, Travers P, Walport M, Shlomchik M. Immunobiology: the immune system in health and disease. Edinburgh, New York: Churchill Livingstone Garland Publ., 2001.
5. Pulendran B., Palucka K., Banchereau J. Sensing pathogens and tuning immune responses. Science. 293:2001;253-256
6. Kelly J.M., Darcy P.K., Markby J.L., Godfrey D.I., Takeda K., Yagita H., et al. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat. Immunol. 3:2002;83-90
7. Geldhof A.B., Van Ginderachter J.A., Liu Y., Noel W., Raes G., De Baetselier P. Antagonistic effect of NK cells on alternatively activated monocytes: a contribution of NK cells to CTL generation. Blood. 100:2002;4049-4058
8. Kos F.J. Regulation of adaptive immunity by natural killer cells. Immunol. Res. 17:1998;303-312
9. Kasaian M.T., Whitters M.J., Carter L.L., Lowe L.D., Jussif J.M., Deng B., et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity. 16:2002;559-569
10. Fichtner I., Lemm M., Becker M., Berthold F. Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas. Anticancer Drugs. 8:1997;174-181
11. Zou Y., Muller W., Gu H., Rajewsky K. Cre-loxP-mediated gene replacement: a mouse strain producing humanized antibodies. Curr. Biol. 4:1994;1099-1103
12. Hombach A., Tillmann T., Jensen M., Heuser C., Sircar R., Diehl V., et al. Specific activation of resting T cells against tumour cells by bispecific antibodies and CD28-mediated costimulation is accompanied by Th1 differentiation and recruitment of MHC-independent cytotoxicity. Clin. Exp. Immunol. 108:1997;352-357
13. Trotter J. WinMDI v.2.8, 2000. http://www.fz-borstel.de/ ZentrEinrichtungen/flowcytes/software/software.htm.
14. Ollert M.W., David K., Schmitt C., Hauenschild A., Bredehorst R., Erttmann R., et al. Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells. Proc. Natl. Acad. Sci. U.S.A. 93:1996;4498-4503
15. Murray J.L., Cunningham J.E., Brewer H., Mujoo K., Zukiwski A.A., Podoloff D.A., Kasi L.P., Bhadkamkar V., Fritsche H.A., Benjamin R.S. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J. Clin. Oncol. 12:1994;184-193
16. Reuland P., Geiger L., Thelen M.H., Handgretinger R., Haase B., Muller-Schauenburg W., Niethammer D., Bares R. Follow-up in neuroblastoma: comparison of metaiodobenzylguanidine and a chimeric anti-GD2 antibody for detection of tumor relapse and therapy response. J. Pediatr. Haematol. Oncol. 23:2001;437-442
17. Korsgren M., Persson C.G., Sundler F., Bjerke T., Hansson T., Chambers B.J., et al. Natural killer cells determine development of allergen-induced eosinophilic airway inflammation in mice. J. Exp. Med. 189:1999;553-562
18. Shi F.D., Wang H.B., Li H., Hong S., Taniguchi M., Link H., et al. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat. Immunol. 1:2000;245-251
19. Gao N., Dang T., Yuan D. IFN-gamma-dependent and -independent initiation of switch recombination by NK cells. J. Immunol. 167:2001;2011-2018
20. Strbo N., Oizumi S., Sotosek-Tokmadzic V., Podack E.R. Perforin is required for innate and adaptive immunity induced by heat shock protein gp96. Immunity. 18:2003;381-390
21. Liu Z.X., Govindarajan S., Okamoto S., Dennert G. NK cells cause liver injury and facilitate the induction of T cell-mediated immunity to a viral liver infection. J. Immunol. 164:2000;6480-6486
22. ASGM1, WAKO BioProducts, 2003, p. 6.
23. Kurita H., Kamei T., Nagaoka K., Yoshida T., Taniwaki H., Ono Y., et al. Natural killer cell activity in mice after intraperitoneal administration of beryylium chloride. J. Occup. Health. 43:2001;284-286